TICKERNERD
Menu
AGENAGENHealthcare · Biotechnology

AGEN Stock Forecast: Agenus, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$7.67
−5.19% on the day

The 2 Wall Street analysts covering Agenus, Inc. hold a median 12-month price target of $20 — +154.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$364.1M
Ticker Nerd rank
88 / 100
Median analyst target
$20
Analysts covering
2
Total return, dividends reinvested
1W
+7.3%
1M
+28.3%
YTD
+144.3%
1Y
+69.7%
From 52W high
−7.6%
From 52W low
+176.9%
$2.77
$8.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Agenus, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
88 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Value
95
Quality
95
Momentum
70
Issuance
68
Size
59
Accruals
42
Revisions
40
Volatility
22

Growth (99): Sales and profits are climbing, and climbing faster than before.

Volatility (22): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00Oct 25Jan 26Apr 26Jul 26AGENHigh $25Median $20Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2 Buy0 Hold0 Sell
Low $14Median $20High $25

The green dot is the last close — the median target sits +154.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
11 Aug 2026HC Wainwright & Co.MaintainsBuy$30 → $25
30 July 2026B. Riley SecuritiesMaintainsBuy$8.00 → $14
30 July 2026B. Riley SecuritiesMaintainsBuy—
13 July 2026HC Wainwright & Co.MaintainsBuy$23 → $30
13 July 2026HC Wainwright & Co.MaintainsBuy—
10 Sept 2025HC Wainwright & Co.ReiteratesBuy—
28 Aug 2025HC Wainwright & Co.ReiteratesBuy—
4 June 2025BairdMaintainsNeutral—
4 June 2025HC Wainwright & Co.UpgradeBuy—
13 May 2025BairdMaintainsNeutral—
13 May 2025HC Wainwright & Co.ReiteratesNeutral—
30 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
18 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
12 Mar 2025BairdMaintainsNeutral—
12 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
22 Jan 2025HC Wainwright & Co.ReiteratesNeutral—
5 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
29 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
12 Nov 2024HC Wainwright & Co.MaintainsNeutral—
14 Aug 2024B. Riley SecuritiesMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AGEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Agenus, Inc. (AGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.7×

Cheaper than 69% of US stocks

Price / sales
2.7×

Cheaper than 45% of US stocks

Price / book
−1.6×

Cheaper than 95% of US stocks

EV / EBITDA
9.3×

Cheaper than 41% of US stocks

Growth & margins
Revenue growth (YoY)
34.4%

Higher than 80% of US stocks

Earnings growth (YoY)
34.4%

Higher than 69% of US stocks

Gross margin
57.2%

Higher than 71% of US stocks

Operating margin
32.7%

Higher than 88% of US stocks

Net margin
69.3%

Higher than 98% of US stocks

Returns & dividend
Return on equity
0.0%

Higher than 44% of US stocks

Return on assets
12.5%

Higher than 95% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AGENAgenus, Inc.$364.1M
88
ZNTLZentalis Pharmaceuticals, Inc.$362.1M
63
CAPRCapricor Therapeutics, Inc.$361.7M
13
PALIPalisade Bio, Inc.$366.0M
36
GALTGalectin Therapeutics, Inc.$371.1M
77
IPSCCentury Therapeutics, Inc.$371.9M
39
DMACDiaMedica Therapeutics, Inc.$351.6M
48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Agenus, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AGEN news & analysis

Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 7 Aug 2026positive

Agenus reported a second-quarter loss of $0.01 per share, narrower than the Zacks Consensus Estimate, compared with a $1.00 per-share loss a year earlier. Revenue came in above estimates, according to the report.

Why it matters — AGEN watchers would note that the company's quarterly loss was smaller than expected and revenues topped estimates, indicating performance was better than analysts anticipated.

Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer

Business Wire · 6 Aug 2026positive

Agenus reported financial results for the second quarter ended June 30, 2026, and provided an update on its financing-supported strategy to advance the Phase 3 ROBBIN trial of botensilimab plus balstilimab (BOT+BAL) in the neoadjuvant, curative-intent setting for high-risk, resectable microsatellite-stable (MSS) colon cancer.

Why it matters — AGEN watchers would care because the company is progressing its lead immuno-oncology combination into a Phase 3 trial in a curative-intent setting for MSS colon cancer, a key pipeline milestone for the company.

Agenus (AGEN) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research · 30 July 2026neutral

Zacks Investment Research reported that Agenus (AGEN) lacks the key ingredients for a likely earnings beat in its upcoming report, advising investors to review the key expectations.

Why it matters — AGEN watchers would care because the report suggests the company may face challenges meeting earnings expectations in its next quarterly release.

Agenus to Provide Second Quarter 2026 Financial Report and Development Update

Business Wire · 28 July 2026neutral

Agenus announced it will release its second quarter 2026 financial results before market open on August 6, 2026, and will host a webcast later in August to discuss corporate priorities, including progress on the BOT+BAL immunotherapy combination in the Phase 3 ROBBIN trial for neoadjuvant colon cancer.

Why it matters — AGEN watchers will be watching for updates on the company's financial position and clinical progress of its lead immunotherapy combination in the neoadjuvant colon cancer setting.

FAQ

Frequently asked questions about AGEN stock

What is the AGEN stock price forecast for 2026-2027?

The 2 Wall Street analysts covering Agenus, Inc. have a median 12-month price target of $20, with estimates ranging from $14 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AGEN stock a buy right now?

Of the 2 analysts covering Agenus, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Agenus, Inc. 88 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AGEN?

As at 22 Aug 2026, Agenus, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will AGEN stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts implies +154.2% from the last close, and Ticker Nerd's factor model ranks Agenus, Inc. 88 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AGEN stock forecast for 2030?

No analyst covering Agenus, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $25 over the next 12 months.

How has AGEN stock performed over the past year?

Agenus, Inc. returned +69.7% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Agenus, Inc. do?

Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and the development of therapies designed to activate the immune system against cancer.

What is the latest news on AGEN?

The most recent item we track (Zacks Investment Research, 7 Aug 2026): "Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates". Agenus reported a second-quarter loss of $0.01 per share, narrower than the Zacks Consensus Estimate, compared with a $1.00 per-share loss a year earlier. Revenue came in above estimates, according to the report.

Company

About Agenus, Inc.

Agenus Inc. is a clinical-stage biotechnology company focused on immuno-oncology and the development of therapies designed to activate the immune system against cancer. The company’s current work centers on antibody-based therapeutics, immune checkpoint modulators, cell therapies, vaccines, and vaccine adjuvants, supported by proprietary discovery and manufacturing capabilities. Its pipeline includes programs intended for solid tumors and other difficult-to-treat cancers, with activities spanning research, clinical development, and translational science. Agenus also operates through its subsidiaries and technology platforms to support antibody discovery and cell-therapy development, reflecting a vertically integrated model in biotechnology. Headquartered in Lexington, Massachusetts, and founded in 1994, Agenus serves as a development-stage company within the broader life sciences market, where it contributes to cancer immunotherapy innovation and clinical research.

CEO Dr. Garo H. Armen Ph.D. · 81 employees · United States · https://www.agenusbio.com